OXBRYTA is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Global Blood Therapeutics Inc.. The primary component is Voxelotor.
Product ID | 72786-102_0f829f12-5b00-4e7f-9261-377702f5a2a3 |
NDC | 72786-102 |
Product Type | Human Prescription Drug |
Proprietary Name | OXBRYTA |
Generic Name | Voxelotor |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2019-11-25 |
Marketing Category | NDA / |
Application Number | NDA213137 |
Labeler Name | Global Blood Therapeutics Inc. |
Substance Name | VOXELOTOR |
Active Ingredient Strength | 300 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-10-14 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
72786-101 | OXBRYTA | Voxelotor |
72786-102 | OXBRYTA | Voxelotor |
72786-111 | OXBRYTA | Voxelotor |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
![]() OXBRYTA 88415216 not registered Live/Pending |
Global Blood Therapeutics, Inc. 2019-05-03 |
![]() OXBRYTA 87721060 not registered Live/Pending |
Global Blood Therapeutics, Inc. 2017-12-14 |